For the year ending 2025-12-31, MAZE had -$7,565K decrease in cash & cash equivalents over the period. -$112,734K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net (loss) income | -131,120 |
| Depreciation expense | 2,403 |
| Stock-based compensation expense | 16,400 |
| Non-cash lease expense | 3,134 |
| Accretion of discounts on marketable securities, net | 505 |
| Other items, net | 21 |
| Prepaid expenses and other current assets | 2,941 |
| Other assets | -537 |
| Accounts payable | -27 |
| Accrued expenses and other liabilities | 3,482 |
| Operating lease liabilities | -3,324 |
| Net cash (used in) provided by operating activities | -111,940 |
| Purchases of marketable securities | 187,668 |
| Maturities of marketable securities | 17,500 |
| Purchases of property and equipment | 794 |
| Net cash used in investing activities | -170,962 |
| Proceeds from initial public offering, net of offering costs paid | 127,752 |
| Proceeds from private placement, net of offering costs paid | 141,267 |
| Proceeds from exercise of stock option awards, net of repurchases | 5,561 |
| Proceeds from issuance of common stock under the 2025 employee stock purchase plan | 1,256 |
| Payment of success fee derivative | 500 |
| Proceeds from exercise of pre-funded warrants | 1 |
| Net cash provided by financing activities | 275,337 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -7,565 |
| Cash, cash equivalents and restricted cash at beginning of year | 197,900 |
| Cash, cash equivalents and restricted cash at end of year | 190,335 |
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)